Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?
Open Access
- 1 December 2010
- journal article
- Published by Informa UK Limited in Biologics: Targets and Therapy
- Vol. 4, 325-332
- https://doi.org/10.2147/btt.s14902
Abstract
Botulinum toxin type A is a high molecular weight protein complex containing active neurotoxin and complexing proteins, the latter of which, it is believed, protect the neurotoxin when in the gastrointestinal tract, and may facilitate its absorption. Comparisons of conventional botulinum toxin type A drugs that include complexing proteins with the complexing protein-free formulation of Xeomin® strongly suggest that complexing proteins do not affect diffusion of the active neurotoxin. Studies of Xeomin have also shown that complexing proteins do not enhance product stability in storage. However, complexing proteins may stimulate antibody development against botulinum toxin type A. Numerous observational studies have been published showing that some patients receiving conventional botulinum toxin may develop neutralizing antibodies, leading to antibody-induced therapy failure. Studies have shown that Xeomin is not associated with the development of neutralizing antibodies in animal models or in patients. In conclusion, complexing proteins do not contribute to the stability of botulinum toxin type A drugs and do not contribute to their therapeutic effects, but may be associated with a secondary nonresponse due to the development of neutralizing antibodies.Keywords
This publication has 41 references indexed in Scilit:
- Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticityJournal of Neural Transmission, 2009
- Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins – differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type CMicrobiology, 2009
- Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failureInternational Journal of Urology, 2008
- Evidence for effectiveness of botulinum toxin for hyperhidrosisJournal of Neural Transmission, 2007
- Neurophysiological Double-Blind Trial of a Botulinum Neurotoxin Type A Free of Complexing ProteinsClinical Neuropharmacology, 2007
- Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applicationsJournal of Cosmetic and Laser Therapy, 2007
- New formulation of Botox: complete antibody-induced treatment failure in cervical dystoniaJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN??) in Focal DystoniaDrugs, 2007
- Transport of Bacterial Toxins into Target Cells: Pathways Followed by Cholera Toxin and Botulinum Progenitor ToxinThe Journal of Biochemistry, 2006
- Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX°) in healthy volunteersJournal of Neural Transmission, 2004